Core C is designed to meet the specific needs of the projects and at the same time draw on the strength of the existing Cancer Center (CC) cores without unnecessary duplication of services. This Core will work closely and synergistically with a number of CC Cores as well as other SPORE Cores to provide exceptional support for all the proposed projects and possible inter-SPORE collaborations. The overarching goals of this core is to provide high quality, well annotated and strictly quality controlled biospecimens for the projects, to develop and implement assays needed for the analysis of the biospecimens and to collaborate with Core B to build the informatics infrastructures to facilitate all aspects of research linked to biospecimens.
Specific Aim 1 is to provides services in the following areas: (1) acquisition and banking of fresh and paraffin- fixed tissues of lymphoma and blood and bone marrow (BM) samples obtained prospectively and retrospectively from patients enrolled on the COH lymphoma SPORE; we will ensure rapid collection and processing, proper storage and monitoring, and proper annotation and record keeping; (2) comprehensive work-up of lymphoma specimens to ensure correct diagnosis and classification, including immunohistochemical, flow cytometric, molecular pathologic, and cytogenetic studies; (3) performance and assistance in routine histologic and immunohistochemical staining of lymphoma tissues and cells, as well as specialized histologic services such as preparation of multi-tumor blocks or tissue microarrays to the specifications of researchers. Additional specialized services will be performed according to the needs of the projects with the collection of leukapheresis specimens to generate CAR-T cells (Project 1); characterization of complex Hodgkin lymphoma and host cell populations through multispectral multiplexed immunofluorescence (mIF) phenotyping and gene expression profiling (GEP) (Project 3); cytogenetic and genomic characterization of lymphomas and the preparation of samples to generate primary patient-derived xenograft (PDX) non- Hodgkin lymphoma models (Project 4). Because of the complexity of the datasets associated with the functions of Core C, in Specific Aim 2, we will collaborate with Core B (Research Informatics) to design, build, and integrate databases relevant to biospecimens to improve their functionality and connectivity to support SPORE projects and collaborations on other NCI-sponsored projects.

Public Health Relevance

Core C will facilitate research on lymphoid malignancies by SPORE investigators and other lymphoma researchers through the acquisition and banking of high quality tissues from lymphoma patients, providing quality control and management, comprehensive pathological characterization, and assistance with specialized studies specific to the SPORE projects. While Core C is designed to complement and support the projects, it will at the same time draw on the strength of the existing infrastructure and leverage the expertise of other NCI- funded resources already present at our institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA107399-11A1
Application #
9418461
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrmann, Andreas; Lahtz, Christoph; Nagao, Toshikage et al. (2017) CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. Cancer Res 77:5118-5128
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Herrera, Alex F; Armand, Philippe (2017) Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. J Clin Oncol 35:3877-3887
Won, Haejung; Moreira, Dayson; Gao, Chan et al. (2017) TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. J Leukoc Biol 102:423-436
Gibson, Christopher J; Lindsley, R Coleman; Tchekmedyian, Vatche et al. (2017) Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol 35:1598-1605
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2017) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant :
Urak, Ryan; Walter, Miriam; Lim, Laura et al. (2017) Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J Immunother Cancer 5:26
Zhang, Chunyan; Xin, Hong; Zhang, Wang et al. (2016) CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity 44:913-923
Beharry, Andrew A; Lacoste, Sandrine; O'Connor, Timothy R et al. (2016) Fluorescence Monitoring of the Oxidative Repair of DNA Alkylation Damage by ALKBH3, a Prostate Cancer Marker. J Am Chem Soc 138:3647-50

Showing the most recent 10 out of 88 publications